Scilex Holding Company
Index- P/E68.43 EPS (ttm)0.13 Insider Own96.20% Shs Outstand13.18M Perf Week-8.72%
Market Cap1.24B Forward P/E- EPS next Y- Insider Trans0.00% Shs Float5.30M Perf Month149.00%
Income1.80M PEG- EPS next Q- Inst Own9.20% Short Float / Ratio4.49% / 1.20 Perf Quarter-16.60%
Sales34.38M P/S36.08 EPS this Y- Inst Trans-10.52% Short Interest0.24M Perf Half Y-15.14%
Book/sh6.78 P/B1.28 EPS next Y- ROA1.30% Target Price- Perf Year-13.45%
Cash/sh0.00 P/C- EPS next 5Y- ROE1.60% 52W Range2.87 - 11.69 Perf YTD117.79%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-25.66% Beta-
Dividend %- Quick Ratio0.20 Sales past 5Y- Gross Margin- 52W Low202.79% ATR1.58
Employees2 Current Ratio0.20 Sales Q/Q36.70% Oper. Margin- RSI (14)57.59 Volatility34.75% 27.09%
OptionableNo Debt/Eq0.00 EPS Q/Q88.10% Profit Margin- Rel Volume1.76 Prev Close8.81
ShortableNo LT Debt/Eq0.00 Earnings- Payout0.00% Avg Volume197.58K Price8.69
Recom- SMA2021.00% SMA5056.70% SMA200-4.06% Volume347,734 Change-1.36%
Jan-20-23 10:24AM
Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain. Its commercial product is ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase III clinical trial to treat lumbosacral radicular pain; SP-103, which is in Phase II clinical trail for the treatment of low back pain; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trial for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.